Gale Smith

VP, Discovery and Preclinical Research and Chief Scientist at Novavax

Dr. Smith is vice president of discovery and preclinical research and chief scientist. He is a leader in vaccine technology and holds numerous patents for the baculovirus-insect cell expression system and seasonal influenza vaccines and adjuvants. At Novavax, Dr. Smith has developed the first known commercial, scalable process for the manufacture of virus-like particle vaccines for seasonal influenza. He has also collaborated with the US Centers for Disease Control and Prevention in testing a virus-like particle vaccine to protect animals against the H9N2 influenza. Prior to joining Novavax in January 2004 as vice president of vaccine development, Dr. Smith led a team at Protein Sciences Corp. that developed the first experimental vaccine for HIV to be approved by the US Food and Drug Administration for testing in the United States. Dr. Smith also collaborated with the National Institute of Allergy and Infectious Diseases and the National Institute of Health to produce the first experimental vaccine tested in man against the H5N1 avian influenza. Dr. Smith received a bachelor of science degree in microbiology from University of North Dakota. He did graduate work at the Baylor College of Medicine. Dr. Smith received a doctor of philosophy in microbiology from Texas A&M University.
By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.